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Impaired Expression of MAPK Is Associated with the Downregulation 
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Background: Healthy individuals who develop nontuberculous mycobacteria (NTM) lung disease are likely to have 
specific susceptibility factors which can lead to a NTM infection. The aim of the present study was to investigate 
the mechanism underlying innate immune responses, including the role of mitogen-activated protein kinase 
(MAPK), in Mycobacterium abscessus lung disease.
Methods: Extracellular signal-regulated kinase (ERK1/2) and p38 MAPK expression in monocytes from peripheral 
blood mononuclear cells were measured by Western blot analysis after stimulation by Mycobacterium avium in 
five patients with M. abscessus lung disease and seven healthy controls. A M. avium-induced cytokine assay was 
performed after inhibition of ERK1/2 and p38 MAPK pathways.
Results: Mycobacterium avium induced p38 and ERK1/2 expression in monocytes from healthy controls and 
subsequently upregulated tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-10 production. In monocytes 
from patients with M. abscessus lung disease, however, induction of p38 and ERK1/2 expression, and the 
production of TNF-α, IL-6, and IL-10 were significantly lower.
Conclusion: Decreased activity of MAPK and cytokine secretion in monocytes from patients with M. abscessus lung 
disease may provide an explanation regarding host susceptibility to these uncommon infections.
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Introduction
  Mycobacterium abscessus belongs to a group of rap-
idly growing mycobacteria that cause a wide spectrum 
of infections in humans including pulmonary, skin, soft 
tissue, and bone disease1,2. Since M. abscessus is re-
sistant in vitro to many antibiotics, obtaining a success-
ful treatment outcome is difficult, especially in patients 
with pulmonary disease3-6.
  Numerous lung diseases cases associated with non-
tuberculous mycobacteria (NTM), including M. ab-
scessus, are elderly women without predisposing risk 
factors such as preexisting lung disease or demonstrable 
immunodeficiency2,7-10. Since NTM are ubiquitous in the 
environment (e.g., soil and water) and disease occur-
rence is uncommon, normal host defense mechanisms 
must be sufficiently effective to prevent infection8. 
Therefore, otherwise healthy individuals who develop 
NTM lung disease are likely to have specific suscepti-
bility factors that lead to NTM infection.
  Toll-like receptors (TLRs) play a critical role in the 
recognition of mycobacterial infection and function in 
the host's innate defense response11-13. TLR2 is re-
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Table 1. Baseline characteristics of five patients with Mycobacterium abscessus lung disease and 7 healthy controls
Characteristics Patients Controls
Age, yr   64 (54∼66) 46 (45∼49)
Gender, female    4 (80)  7 (100)
Body mass index, kg/m2 20.5 (18.8∼23.2)   NA
Non-smoker    4 (80)   NA
Previous history of tuberculosis    2 (40)   None
Positive sputum AFB smear at diagnosis    2 (40)     −
Type of disease     −
  Nodular bronchiectatic form    4 (80)
  Upper lobe cavitary form    1 (20)
Data are presented as number or median (interquartile range or percentage).
AFB: acid-fast bacilli; NA: not available.
portedly required for NTM signaling and increased rates 
of M. avium infection are observed in TLR2-knockout 
mice14. Mitogen-activated protein kinases (MAPKs), 
which are triggered by mycobacteria through engage-
ment of TLRs, are important signal-transducing enzymes 
involved in many facets of cellular regulation and cyto-
kine responses15,16. The MAPK family is composed of 
three major serine-threonine protein kinases including 
p38, extracellular signal-regulated kinase (ERK1/2), and 
the c-Jun NH2-terminal kinase15.
  Several studies have been performed on MAPK sig-
naling in macrophages during NTM infection17-19, which 
suggested that the degree and timing of p38 and ERK1/2 
activation contribute differently in response to myco-
bacterial organisms. While ERK1/2 or p38 signaling are 
responsible for the induction of tumor necrosis factor 
(TNF)-α, a key cytokine involved in granuloma for-
mation during NTM infection, p38 is primarily involved 
in the initiation of interleukin (IL)-10, which is an an-
ti-inflammatory cytokine18,20. MAPK p38 and IL-10 path-
ways might be associated with the survival of myco-
bacterium in the macrophages18,19,21,22. Studies on NTM 
stimulated MAPK pathway have been performed in hu-
man cells12,20, but few studies have examined the MAPK 
pathway in human patients with NTM lung disease as 
compared to healthy controls.
  Our previous study suggested that the downregula-
tion of TLR2 and the resulting decreased production of 
IL-12 p40 and TNF-α following stimulation of M. 
avium may contribute to host susceptibility to NTM lung 
disease11. MAPKs engage TLRs when they initiate the 
immune response15,16. Therefore, we assessed whether 
the expression of MAPKs, known as a critical enzyme 
in immune responses during NTM infection, contribute 
to susceptibility in patients with M. abscessus lung dis-
ease as compared to healthy controls.
Materials and Methods
1. Study population
  The present study included five patients with M. ab-
scessus lung disease and seven healthy volunteers. The 
diagnosis of M. abscessus lung disease was made ac-
cording to the diagnostic criteria published by the 
American Thoracic Society2. All patients had character-
istic findings on high-resolution computed tomography 
scans, such as bilateral bronchiectasis combined with 
multiple small nodules and branching linear structures23. 
Baseline characteristics of patients are presented in 
Table 1. M. abscessus was identified using a polymer-
ase chain reaction and restriction length polymorphism 
method based on the rpoB gene, as previously de-
scribed24. Peripheral blood samples of 30 mL were ob-
tained from the controls and patients before antibiotic 
therapy was initiated. This study was approved by the 
Institutional Review Board at our institution and written 
informed consent was obtained from all participants.
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2. Preparation and stimulation of human monocytes
  Peripheral blood mononuclear cells (PBMCs) were 
separated from heparinized whole blood using standard 
density gradient centrifugation with Ficoll-PaqueTM (GE- 
Healthcare, Uppsala, Sweden). Cells were incubated for 
1 hour at 37oC, and non-adherent cells were removed 
by pipetting off the supernatant. Adherent monocytes 
were then resuspended at a density of 1×105 cells/well 
in RPMI-1640 medium (Life Technologies, Grand Island, 
NY, USA) for the cytokine assay and at a density of 
3×105 cells/well for the MAPK assay.
  Monocytes were stimulated with either M. avium 
(American Type Culture Collection 25291; ATCC, Mana-
ssas, VA, USA) which was obtained from the Korean 
Institute of Tuberculosis, at a multiplicity of infection 
(MOI) of 70 or lipoteichoic acid (LTA) from Staphylo-
coccus aureus (10μg/mL; InvivoGen, San Diego, CA, 
USA) and incubated at 37oC for 18 hours. The prelimi-
nary data of healthy human sample under different MOI 
showed peak level of TNF-α production over MOI of 
50. Cell-free (cleared) supernatant fractions were col-
lected and analyzed for cytokine release.
3. Cytokine assay
  Culture supernatants were collected at 18 hours to ex-
amine cytokine release from monocytes following M. 
avium and LTA stimulation. The concentrations of IL-10, 
IL-6, and TNF-α in the culture supernatants were meas-
ured using commercially available enzyme-linked im-
munosorbent assays kits (BioSource, Camarillo, CA, 
USA).
  Cytokine concentrations in samples were calculated 
using standard curves generated from recombinant cyto-
kines, and the results were expressed in picograms per 
milliliter.
4. Signaling inhibition assays
  Human monocytes (3×105 cells/well) were pre-
treated with 10μg/mL of anti-TLR2-specific antibody 
(eBioscience, San Diego, CA, USA), 10μg/mL of the 
p38 signaling inhibitor SB203580 (Calbiochem, San 
Diego, CA, USA) or 20μg/mL of the ERK1/2 selective 
inhibitor PD98059 (Calbiochem) for 90 minutes prior to 
stimulation. Cells were then stimulated with M. avium 
or LTA. Culture supernatants were harvested and as-
sayed for cytokine activity.
5. p38 and ERK1/2 assays
  Following stimulation, the human monocytes (3×105 
cells/well) were harvested and lysed. For Western blot 
analysis, samples were separated on 8% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, transferred to 
a polyvinylidene difluoride membrane (Invitrogen Life 
Technologies, San Diego, CA, USA), and immuno-
blotted with the antibodies anti-phospho-p38, anti-p38, 
anti-phospho-ERK, anti-ERK (Cell Signaling Technology, 
Danvers, MA, USA), and anti-β-actin (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). The reaction was de-
tected using an ECL Plus western blotting detection sys-
tem (Amersham, GE-Healthcare, Buckinghamshire, UK), 
an enhanced chemiluminescence detection system.
6. Statistical analysis
  Differences in each variable between patients and 
controls were evaluated with Mann-Whitney U-tests and 
a Wilcoxon test. A p-value less than 0.05 was consid-
ered statistically significant.
Results
1. NTM leads to the phosphorylation of MAPKs in 
monocytes of patients with M. abscessus lung 
disease, but expression of MAPKs in patients is 
less than that of healthy controls
  Because NTM-induced expression of MAPKs in heal-
thy human monocytes has been confirmed in other 
studies, we examined whether MAPKs are activated in 
monocytes of patients with M. abscessus lung disease 
after stimulation with NTM. We then compared the ex-
pression levels of MAPKs in monocytes between the pa-
tients and healthy controls.
  Western blot analysis with anti-phospho-ERK1/2 in 
patients showed that ERK1/2 activity after M. avium 
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Figure 1. Mycobacterium avium-induced extracellular signal-regulated kinase (ERK1/2) and p38 expression in peripheral
blood monocytes from patients with M. abscessus lung disease and healthy controls. ERK1/2 (A) and p38 (B) activation
with M. avium or lipoteichoic acid (LTA) significantly decreased in patients (gray bar) as compared to healthy controls
(white bar). Expression of ERK1/2 and p38 via inhibition with the anti-TLR2 antibody were not different between patients
and controls. *p＜0.05. †p＜0.01. TLR2 Ab: Toll-like receptor 2 antibody.
stimulation (MOI 1:70) was upregulated as compared to 
ERK1/2 in the non-stimulated state (p=0.018) (Figure 
1A). ERK1/2 expression after LTA showed similar results 
(p=0.043), although the expression of ERK1/2 in pa-
tients was lower than that of healthy controls in re-
sponse to M. avium stimulation (p=0.010), despite the 
small difference in ERK1/2 expression during the 
non-stimulated state between the patients and healthy 
controls (Figure 1A). Similar profiles were observed 
with response to p38 activation between patients with 
M. abscessus lung disease and healthy controls (Figure 
1B).
  After inhibition with a TLR2 neutralized antibody in 
healthy controls, expression of ERK1/2 after M. avium 
stimulation was lower than ERK1/2 without TLR2 in-
hibition (p=0.018). However, it did not differ sig-
nificantly from ERK1/2 activation in the patients after 
TLR2 inhibition with the antibody (Figure 1A). Thus, the 
expression of ERK1/2 in response to M. avium stim-
ulation with TLR2 inhibition was not different between 
the patients and controls, in contrast to significant differ-
ences of ERK1/2 between patients and controls after M. 
avium stimulation without TLR2 inhibition (Figure 1A). 
The expression of p38 showed a similar tendency 
(Figure 1B).
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Figure 2. (A∼C) Inhibitory effects of extracellular sig-
nal-regulated kinase (ERK1/2) and p38 on Mycobacterium 
avium-induced tumor necrosis factor (TNF)-α, interleukin 
(IL)-6, and IL-10 in monocytes from patients with M. ab-
scessus lung disease and healthy controls. The anti-TLR2- 
specific antibody, the p38 signaling inhibitor SB203580 
(SB), or the ERK1/2 selective inhibitor PD98059 (PD) prior 
to infection with M. avium at a MOI of 70 was added to 
the cells. The supernatants were harvested and ELISA was 
used to measure cytokine activity. *p＜0.05. †p＜0.01. 
TLR2 Ab: toll-like receptor 2 antibody; MOI: multiplicity of 
infection; ELISA: enzyme-linked immunosorbent assays; 
controls: white bar; patients: gray bar.
2. NTM-induced cytokine production in human mono-
cytes is dependent on ERK1/2 and p38, but lower 
cytokine levels were observed in patients with M. 
abscessus lung disease as compared to healthy 
controls
  To determine whether MAPK activation was neces-
sary for NTM-induced cytokine production, human 
monocytes were pretreated with the ERK1/2 inhibitor 
PD98059 or the p38 inhibitor SB203580 prior to M. 
avium stimulation.
  In human monocytes from healthy controls, TNF-α 
secretion significantly increased after M. avium stim-
ulation (MOI 1:70) as compared to the non-stimulated 
state (p=0.018). In contrast, inhibition of ERK1/2 or p38 
reduced TNF-α production by M. avium stimulation 
(Figure 2A). Similar results were obtained with IL-6 pro-
duction (Figure 2B). Moreover, IL-10 production after 
M. avium stimulation was suppressed by the inhibition 
of p38, but not the inhibition of ERK1/2 in healthy con-
trols (Figure 2C).
  We compared cytokine production in monocytes 
from patients with M. abscessus lung disease versus 
healthy controls in the presence and absence of ERK1/2 
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or p38 inhibition followed by M. avium stimulation. 
TNF-α secretion in response to M. avium stimulation 
was lower in patients as compared to the controls 
(p=0.003). However, M. avium-induced TNF-α pro-
duction after blocking ERK1/2 or p38 pathway did not 
show significant difference between patients and con-
trols (Figure 2A). A similar tendency was shown in IL-6 
(Figure 2A) and IL-10 (Figure 2C).
Discussion
  To the best of our knowledge, the current study is 
the first to examine MAPK expression in patients with 
NTM lung disease including M. abscessus lung disease. 
The present data demonstrate that both M. avium and 
LTA induce p38 and ERK1/2 expression in monocytes 
from healthy controls, and subsequently upregulate 
TNF-α, IL-6 and IL-10 production. However, in mono-
cytes from patients with M. abscessus lung disease, the 
induction of p38 and ERK1/2 expression, and TNF-α, 
IL-6, and IL-10 production, occurred to a significantly 
lesser extent. IL-10 production is related not only to p38 
but also to the ERK1/2 pathway. Thus, current findings 
suggest that impaired induction of p38 and ERK1/2 ex-
pression in response to M. avium or LTA stimulation 
may contribute to host susceptibility to M. abscessus 
lung disease. For tolerance effect is partly eliminated, 
M. abscessus primed cell is stimulated by M. avium in-
stead of same strain.
  Since NTM are ubiquitous organisms, most people 
are resistant to infection unless their defense mecha-
nisms have undergone iatrogenic alteration. However, 
the nature of the precise immune dysfunction that pre-
disposes otherwise healthy subjects to NTM lung dis-
ease are not clear. A few studies that have compared 
the immune responses of PBMCs from patients with 
NTM lung disease and healthy controls have shown that 
patients produce lower concentrations of IL-12, interfer-
on-γ, and TNF-α25-28. These results suggest that sus-
ceptibility to NTM lung disease is related to the sup-
pression of the T-helper cell (Th) type 1 immune 
responses. Downregulation of TLR2 was suggested to 
be involved in the immune suppression of NTM dis-
ease26. However, additional detailed mechanisms re-
sponsible for this immunologic imbalance remain 
unknown.
  MAPK is involved in cytokine responses and in-
flammation linked to the engagement of TLR2 and mye-
loid differentiation factor 88 as demonstrated for 
NTM13,16,29. The present Western blot data show that p38 
and ERK1/2 expression decreases with inhibition by the 
TLR2 antibody. These findings suggest that MAPK sig-
naling pathway is related to the TLR2 pathway.
  TNF-α is thought to mediate pathologic inflamma-
tory reactions and protective responses to mycobacterial 
infections and to play a central role in granuloma for-
mation, both directly and through the recruitment of 
chemokines30. Although IL-6 has been shown to pro-
mote the intracellular growth of mycobacteria in mono-
nuclear cells31,32 IL-6 seems to be critical in resistance 
to mycobacterial infection33. Therefore, down-regulation 
of these cytokine in human with mycobacterial infection 
leads to disease development. In this study, TNF-α and 
IL-6 secretion decreased following stimulation with M. 
avium and LTA when pretreated with p38 inhibitor and 
ERK1/2 inhibitor. These findings strongly suggest that 
p38 and ERK1/2 play essential roles in the production 
of TNF-α and IL-6 against M. avium. Previous studies 
have revealed that TNF-α, IL-6, and IL-10 production 
in M. avium or M. abscessus infection are increased by 
activation of the p38 and ERK1/2 MAPK signaling path-
way in PBMCs of healthy humans12. M. abscessus was 
demonstrated to be activated by the p38 and ERK1/2 
MAPK pathways and induces the secretion of TNF-α, 
IL-6, and IL-12 p40 via TLR2 in murine macrophages13. 
Some studies have indicated that p38 and ERK activa-
tion are required for mycobacteria-induced TNF-α se-
cretion17,34,35.
  IL-10 is an anti-inflammatory cytokine mostly pro-
duced by Th2 cells. Previous studies have shown that 
Th2 immune responses might increase in NTM lung dis-
ease since IL-10 is higher, whereas other cytokines are 
lower in patients with NTM lung disease25,28. However, 
the present data showed that IL-10 production was low-
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er in patients with NTM lung disease than healthy con-
trols and it decreased significantly with inhibition of p38 
signaling. These findings suggest that the ERK1/2 and 
p38 MAPK pathways are critical for M. avium-induced 
TNF-α and IL-6 formation, whereas only the p38 MAPK 
pathway is essential for M. avium-induced IL-10 pro-
duction. Recent studies have found that IL-10 was great-
ly reduced (＞90%) by the p38 inhibitor, whereas the 
ERK1/2 inhibitor only partially interfered with IL-10 (35
∼45%) in study on healthy human monocytes stimu-
lated with M. avium or M. abscessus12. Another study 
of human macrophage stimulated with M. avium show-
ed that induction of IL-10 was critically dependent on 
p38 MAPK activity, but only partially dependent on the 
ERK1/2 pathway36. Such divergent requirements for the 
MAPK pathway of TNF-α and IL-10 might affect regu-
lation of production of inflammatory and anti-inflam-
matory cytokine in NTM infection, although further 
study of type of cell or another strain is requirement. 
Furthermore, this different MAPK role of TNF-α and 
IL-10 will be considered for the usage of MAPK pathway 
of novel target therapy.
  Although these findings strongly suggest that regu-
lation of the p38 and ERK1/2 MAPK pathways may be 
an important determinant of NTM infection suscepti-
bility, the relationship between NTM lung disease and 
MAPK and cytokine expression was not fully examined. 
In the present study, p38 and ERK1/2 MAPK expression, 
and TNF-α, IL-6, and IL-10 production in monocytes 
in NTM lung disease were lower than in healthy 
controls. In addition, treatment with the inhibitor of p38 
or ERK1/2 blocked M. avium induced cytokine pro-
duction in monocytes of healthy controls, but only had 
a minimal effect in those of patients. These results in-
dicate that defects in the MAPK pathway are a crucial 
cause for the reduction in cytokine production during 
NTM lung disease. The present study has several im-
portant limitations. First, the sample size in this study 
was relatively small, perhaps too small to make a defi-
nite conclusion. Therefore, the result of this study has 
value of preliminary study. In addition, peripheral 
blood monocytes can reflect the immunoreactivity of 
airway cells, but the immune response of peripheral 
blood monocytes may be confounded due to a lack of 
local immunoregulatory mechanisms present in the 
lung37,38. Therefore, further studies involving MAPK ex-
pression and subsequent cytokine responses using bron-
choalveolar lavage cells will be needed. Finally, depres-
sion of MAPK expression and subsequent down-
regulation of cytokine responses in patients with NTM 
lung disease might be a secondary phenomenon of 
NTM infection, and is not attributable to the suscepti-
bility of patients with the disease. Secondary phenom-
enon is that impairment of immune response or toler-
ance effect for stimulation from other infection coming 
out after NTM infection. Therefore, further studies are 
needed to examine MAPK expression and cytokine re-
sponses before and after treatment of M. abscessus 
infection.
  NTM infection induced p38 and ERK1/2 expression 
in monocytes from healthy controls and subsequently 
upregulated TNF-α and IL-6 production. IL-10 pro-
duction was related to the p38 pathway, but not the 
ERK1/2 pathway. In monocytes from patients with M. 
abscessus lung disease, however, the induction of p38 
and ERK1/2 expression, and the production of TNF-α, 
IL-6, and IL-10 were significantly lower. These findings 
suggest that decreased activity of MAPK and cytokine 
secretion in monocytes from patients with M. abscessus 
lung disease may partially explain the reasons for host 
susceptibility to these uncommon infections.
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